Core Viewpoint - Huakang Biomedical (08622) has appointed Qingtian Capital Limited as an independent financial advisor to provide advice on the offer and its acceptance status to the independent board committee, offer shareholders, and option holders [1] Group 1 - Qingtian Capital Limited has been granted a license to conduct regulated activities under the Securities and Futures Ordinance (Cap. 571) of Hong Kong, specifically for providing advice on institutional financing [1] - The appointment of Qingtian Capital Limited has been approved by the independent board committee in accordance with Rule 2.1 of the Takeovers Code [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED 華康生物醫學控股有限公司 茲 提 述 華 康 生 物 醫 學 控 股 有 限 公 司（「本公司」）與Anselme Limited於二零二五年 十 月 九 日 聯 合 刊 發 的 公 告，內 容 有 關（其 中 包 括）完 成 買 賣 協 議 及 要 約（「聯合公 告」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 聯 合 公 告 所 定 義 者 具 有 相 同 涵 義。 董 事 會 欣 然 宣 佈，擎 天 資 本 有 限 公 司，獲 發 牌 從 事 香 港 法 例 第571章證券及期 貨條例下第6類（就 機 構 融 資 提 供 意 見）受 規 管 活 動 之 法 團，已 獲 委 ...

Core Viewpoint - Anselme Limited has increased its stake in Huakang Biomedical (08622) to 51.84% by acquiring 138.672 million shares at an average price of HKD 0.126 per share, totaling approximately HKD 17.47 million [1] Group 1 - Anselme Limited's recent acquisition involved purchasing 138.672 million shares of Huakang Biomedical [1] - The average price per share for this transaction was HKD 0.126 [1] - Following this transaction, Anselme Limited's total shareholding in Huakang Biomedical is approximately 259 million shares [1] Group 2 - The total amount spent by Anselme Limited for this acquisition was around HKD 17.47 million [1] - The new shareholding percentage of Anselme Limited in Huakang Biomedical is 51.84% [1] - The transaction also involved other related parties, specifically Zhou Xun Yong [1]

Core Viewpoint - Anselme Limited has increased its stake in Huakang Biomedical (08622) by acquiring 138.672 million shares at an average price of HKD 0.126 per share, totaling approximately HKD 17.4727 million, resulting in a new holding of about 259 million shares, representing 51.84% ownership [1] Group 1 - Anselme Limited's acquisition of shares occurred on October 9 [1] - The average price per share for the transaction was HKD 0.126 [1] - The total amount spent on the acquisition was approximately HKD 17.4727 million [1] Group 2 - Following the transaction, Anselme Limited's total shareholding in Huakang Biomedical increased to approximately 259 million shares [1] - The new ownership percentage after the acquisition is 51.84% [1] - The transaction involved other related parties, specifically Zhou Xun Yong [1]

Core Insights - Hong Kong Stock Exchange data indicates that on October 9, Huakang Biomedical (08622) shareholders transferred stocks from Qingtian Securities to Jinlifeng Securities, with a transfer market value of HKD 54.8386 million, accounting for 27.74% of the total [1] Group 1 - On October 9, Huakang Biomedical and the offeror Anselme Limited jointly announced a sale and purchase agreement, where the seller Li Jingyang conditionally agreed to sell and the offeror conditionally agreed to acquire all legal and beneficial ownership and rights of the shares (1.387 billion shares), representing approximately 27.71% of the total issued share capital as of the announcement date, for a total consideration of HKD 17.4727 million, equivalent to HKD 0.126 per share [1]

Core Viewpoint - Huakang Biomedical (08622) announced that its shares will resume trading on October 10, 2025, at 9:00 AM [1] Company Summary - The company has made an official announcement regarding the resumption of its stock trading [1]

10月9日，华康生物医学及要约人Anselme Limited联合公布，于2025年10月9日，要约人(作为买方)与卖 方李景杨(作为卖方)订立买卖协议，卖方有条件同意出售，而要约人有条件同意收购销售股份(即1.387 亿股股份)的全部法定及实益所有权及权益，占本公司于本联合公告日期已发行股本总额约27.71%，总 代价为1747.27万港元，相当于每股销售股份0.126港元。 智通财经APP获悉，香港联交所最新资料显示，10月9日，华康生物医学(08622)股东将股票由擎天证券 转入金利丰证券，转仓市值5483.86万港元，占比27.74%。 ...

Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1][2] Group 2 - The offer price of HKD 0.126 per share represents a discount of approximately 68.10% compared to the closing price of HKD 0.395 per share on the date of the announcement [1] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [3]

智通财经APP讯，华康生物医学(08622)及要约人Anselme Limited联合公布，于2025年10月9日，要约人 (作为买方)与卖方李景杨(作为卖方)订立买卖协议，卖方有条件同意出售，而要约人有条件同意收购销 售股份(即1.387亿股股份)的全部法定及实益所有权及权益，占本公司于本联合公告日期已发行股本总额 约27.71%，总代价为1747.27万港元，相当于每股销售股份0.126港元。 于本联合公告日期，要约人由周训勇博士全资实益拥有，周博士亦为要约人的唯一董事。 本公司已向联交所申请股份自2025年10月10日(星期五)上午九时正起于联交所GEM恢复买卖。 每股要约股份现金0.126港元，较股份于本联合公告日期在联交所所报收市价每股股份0.395港元折让约 68.10%。 紧接完成前，要约人直接及实益拥有1.21亿股股份，相当于本公司已发行股本总额约24.13%。紧随完成 后及于本联合公告日期，要约人、周博士及与彼等任何一方一致行动人士合共拥有2.59亿股股份的权 益，相当于本公司已发行股本总额约51.84%。除上述者外，概无要约人、周博士及与彼等任何一方一 致行动人士于任何其他股份及购股权拥有 ...

华康生物医学(08622)及要约人Anselme Limited联合公布，于2025年10月9日，要约人(作为买方)与卖方 李景杨(作为卖方)订立买卖协议，卖方有条件同意出售，而要约人有条件同意收购销售股份(即1.387亿 股股份)的全部法定及实益所有权及权益，占本公司于本联合公告日期已发行股本总额约27.71%，总代 价为1747.27万港元，相当于每股销售股份0.126港元。 紧接完成前，要约人直接及实益拥有1.21亿股股份，相当于本公司已发行股本总额约24.13%。紧随完成 后及于本联合公告日期，要约人、周博士及与彼等任何一方一致行动人士合共拥有2.59亿股股份的权 益，相当于本公司已发行股本总额约51.84%。除上述者外，概无要约人、周博士及与彼等任何一方一 致行动人士于任何其他股份及购股权拥有权益。根据收购守则规则26.1及13.5，要约人须提出强制性无 条件现金要约，以收购全部已发行股份(要约人及其一致行动人士已拥有或同意收购者除外);及注销全部 尚未行使购股权。 每股要约股份现金0.126港元，较股份于本联合公告日期在联交所所报收市价每股股份0.395港元折让约 68.10%。 于本联合公告日期 ...